Efficacy and safety of vertebroplasty for treatment of painful ... 7thSpace Interactive (press release), NY - Nov 24, 2008 Vertebroplasty is a promising but as yet unproven treatment for painful osteoporotic vertebral fractures. It involves radiographic-guided injection of ...
Nutrition Wise: Osteoporosis Risk in Cancer Survivors, Graham ... Kansas City infoZine, MO - Nov 22, 2008 A: Yes, depending on the type of treatment used, some cancer survivors do seem to be at increased risk for osteoporosis, the disease in which bones become ...
Osteoporosis Drugs May Prevent Future Bone Growth MarketWatch - Nov 13, 2008 Although, PTH injections have been shown to reduce the incidence of fractures by restoring bone, the treatment can be very costly and requires daily ...
Curing Diversity FrontPage magazine.com, CA - Nov 27, 2008 While Congress certainly didn?t anticipate or intend this result in 1962, ?safety first? has emerged as the most potent and politically seductive policy for ...
Ligand Pharmaceuticals Announces Third Quarter Results MarketWatch - Nov 6, 2008 Pfizer -- SERM, Lasofoxifene: The FDA has extended the review period for Pfizer's NDA for FABLYN(R) (lasofoxifene) for the treatment of osteoporosis in ...LGND
Source: Google News
Recent News and Articles on the Keywords: treatment + osteoporosis + 11,000 Related to the article below (Last Update: 8/7/2008)
Postmenopausal osteoporosis: Prevention and treatment with calcitonin - GM Prelevic, EY Adashi - Gynecological Endocrinology, 1992 - informaworld.com ... 161,11000 Belgrade, Yugoslavia 141 ... In women with established osteoporosis, in
the late postmenopausal years, the main goal of treatment is to ...
Corticosteroid-induced osteoporosis in adults G Weryha, M Klein, F Guillemin, J Leclere - Presse Medicale, 1998 - csa.com ... Preventive measures against corticosteroid-induced osteoporosis should begin with treatment onset. ... X 24113 Side effects; H 11000 Diseases/Injuries/Trauma ... -
Tibolone and osteoporosis - G Lazovic, U Radivojevic, V Milosevic, A Lazovic, … - Archives of Gynecology and Obstetrics, 2007 - Springer ... Centre of Serbia, Koste Todorovica 26, 11000 Belgrade, Serbia ... used primarily for
the prevention of postmenopausal osteoporosis and treatment of climacteric ...
- MG Grodberg - US Patent 4,861,590, 1989 - Google Patents ... Ca 2500 3300 4000 5000 5000 7000 10000 11000... providing fluoride ions for the treatment
and prevention of bone loss disease, including osteoporosis and alveolar ...
Safety and efficacy of Risedronate for the treatment of male osteoporosis
A Phase III trial has evaluated the safety and efficacy of Risedronate ( Actonel ) for male osteoporosis.
In the trial, patients treated with Risedronate experienced a statistically significant 4.5 percent ( p<0.0001 ) increase in lumbar spine bone mineral density compared to patients receiving placebo after two years.
The double-blind, randomized, placebo-controlled, parallel group, multicenter study included 284 men ( 95 percent Caucasian ) between the ages of 36 and 84 years, inclusive, who had osteoporosis ( lumbar spine T-score less than or equal to -2.5 and femoral neck T-score less than or equal to -1 SD, or lumbar spine T-score less than or equal to -1 and femoral neck T-score less than or equal to -2 SD ) and not more than one osteoporosis-related fracture.
Study participants were randomized ( 2:1 ) to either Risedronate tablets 35 mg once a week ( n=191 ) or placebo ( n=93 ) and received daily supplements of Calcium ( 1000 mg ) and vitamin D ( 400-500 IU ) for two years.
The primary endpoint was mean percent change from baseline in lumbar spine bone mineral density relative to placebo.
Secondary endpoints included bone mineral density changes at the femoral neck, femoral trochanter, and total proximal femur, as well as percent changes from baseline in bone turnover markers including type I collagen C-telopeptide ( CTx ), type I collagen N-telopeptide/creatinine ( NTx/cr ), and bone-specific alkaline phosphatase (BAP).
Overall, Risedronate was well-tolerated, and adverse events were generally similar between patients receiving Risedronate and patients receiving placebo.
The most commonly reported adverse events were constipation, back pain, arthralgia, influenza, and nasopharyngitis.
Source: International Osteoporosis Foundation ( IOF ) World Congress on Osteoporosis, 2006
